<DOC>
	<DOC>NCT01309295</DOC>
	<brief_summary>This prospective observational study will assess the efficacy and safety of Mircera (methoxy polyethylene glycol-epoetin beta) in clinical practice in patients with chronic kidney disease, in pre-dialysis or on dialysis, initiated on Mircera treatment. Data from each patient will be collected over 12 months of treatment.</brief_summary>
	<brief_title>An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease in Pre-Dialysis or Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Chronic kidney disease, in predialysis or dialysis Appropriate for treatment with Mircera according to current guidelines and Summary of Product Characteristics Anemia due to nonrenal causes Pregnant or lactating women Uncontrolled hypertension Known hypersensitivity to methoxy polyethylene glycolepoetin beta</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>